Barclays
SLS icon

Barclays’s SELLAS Life Sciences SLS Stock Holding History

Barclays’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8M Buy
+801,600
New +$5.53M ﹤0.01% 1403
2026
Q1 		– Sell
-200,000
Closed -$754K – 5395
2025
Q4 		$754K Buy
+200,000
New +$389K ﹤0.01% 3620

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's SLS Position: Q2 2026 in Review

Barclays increased its SELLAS Life Sciences (SLS) stake by 10% in Q2 2026, buying an estimated $23.3K and bringing the position to 35,783 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #3185.

Barclays first reported a position in SLS in Q1 2017 and has held it in 9 quarters since. The position peaked at $1.93M in Q4 2025. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Barclays held 35,783 shares of SELLAS Life Sciences worth $528K as of Q2 2026.
  • Barclays bought 3,371 SELLAS Life Sciences shares in Q2 2026, an estimated $23.3K.
  • SELLAS Life Sciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3185 holding.
  • Barclays first reported a position in SELLAS Life Sciences in Q1 2017 and has held it in 9 quarters since.
  • Barclays's SELLAS Life Sciences position peaked at $1.93M in Q4 2025.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.